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Introduction
Glycosylation is one of the most frequently occurring
co- or post-translational modifications made to proteins
and lipids in the secretion machinery of the cell [1].
More than half of known protein sequences contain the
requisite sequence for N-glycosylation (AsnXxxSer(Thr);
Xxx ≠ Pro), and any serine (Ser) or threonine (Thr)
residue can potentially be glycosylated [2,3]. The
resultant carbohydrate side chains often have very
complex oligosaccharide sequences and concomitant
structural diversity [1–3]. There are two major types of
glycosylation: O-glycosylation, where the sugar is bound
to the hydroxyl of a serine or a threonine residue, and N-
glycosylation, where the sugar is attached to the amide
function of an asparagine in the consensus sequence
Asn-X-Ser/Thr, where X is any residue but a proline [3].
While the protein sequence is completely encoded by
the genome, the sequence and structure of the sugar
moiety, or glycan, only depend on the action of highly
specific and precisely located enzymes known as
glycosyltransferases and glycosidases. Thus, the glycan
structure is determined not only by the nature of the
protein it is bound to, but also by the tissue or cell where
it is made [3]. These carbohydrate side chains modulate
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the interaction of a protein with its environment,
influencing its solubility, activity, and biologic fate. The
function of the glycans covers a wide spectrum, from
relatively trivial to crucial for the growth, development,
and survival of cells and organisms. However, sugars are
often overlooked, compared to the extent of research on
genes and proteins [3]. This is mainly due to their
complexity, which makes them difficult to sequence and
study. Glycan structures cannot be readily obtained
because they cannot be amplified as nucleic acids can,
they generally come as a highly heterogeneous mix of
different species bound to a single protein, they are non-
linear molecules, and there is no universal method to
precisely determine the structure of a glycan species
without making assumptions regarding the biologic
system [4]. Of particular importance are the sialic acids
and sialic acid derivatives that are ubiquitous at the
terminal positions of the oligosaccharides of glyco-
proteins [5–7], which determine the half-lives of many
circulating glycoproteins. The biosynthesis of these
molecules may act as a coding system, since they are
able to interact with high specificity and selectivity with
carbohydrate-binding proteins including lectins [8],
antibodies, receptors, and enzymes. These molecules
are also involved in cell communication such as cell–cell
and cell–matrix interactions and molecular recognition
during tumor development, differentiation, and pro-
gression [1,9,10], which is catalyzed by enzymes of the
sialyltransferase (ST) family [9].
Classification of Sialyltransferases
Altered sialylation, which occurs during certain patho-
logic processes such as tissue inflammation, onco-
genesis, and metastasis, is associated with either en-
hanced or decreased activity of different STs, including
glycoprotein-specific α2,3-, α2,6-, and α2,8-linkage
transferring enzymes and glycolipid-specific α2,3- and
α2,8-linkage transferring enzymes [11–26]. These
STs are classified into four families according to
the carbohydrate linkages they synthesize: the ST3Gal
(α2,3-ST), ST6Gal (α2,6-ST), ST6GalNAc, and ST8Sia
families [27]. Every family can be further classified into
many subtypes. The ST3Gal family includes at least
seven subtypes, ST3Gal I to ST3Gal VI and ST3Gal VI
ubiquitous. The ST6 family includes two large subtypes,
ST6Gal and ST6GalNAc, each of which is further sepa-
rated into many types: the ST6Gal family comprises
ST6Gal I, II, and III, and the ST6GalNAc family is further
classified into ST6GalNAc I to ST6GalNAc VI. The pri-
mary structures deduced from cloned sialyltransferase
cDNAs suggest a putative domain structure with a type
II transmembrane topology. There are no significant
amino acid sequence similarities among these STs,
except in two sialyl motifs, L and S, which are proposed
to be the cytidine monophosphate-sialic acid recognition
and/or catalytic sites [28]. The α2,3 sialic acid linkages
to Gal residues seem to be the most widely expressed,
followed by the α2,6 linkage to Gal or GalNAc [29].
Among these, Thomsen-Friedenreich (TF)3-related blood
group antigens, such as TF (Galβ1-3GalNAcα1-R),
Tn (TF precursor, GalNAcα1-R), and their sialylated
variants, are oncofetal carbohydrate structures. Increases
in β-1,6-branching, sialyl-Lewis epitopes, and sialyl-Tn
antigen (sialylα2,6-GalNAc-Ser/Thr), or general in-
creases in sialylation of cell surface glycoproteins, are
commonly observed in N-linked and O-linked oligo-
saccharides in carcinoma cells [12,23,30], and these
are correlated with tumor prognosis and metastasis.
Carbohydrate changes have been noted in breast can-
cer [21,31–33], colorectal cancer [5,18,30,34–38], lung
cancer [39,40], hepatic carcinoma [41,42], gastric car-
cinoma [43], head and neck squamous cell carcinoma
(SCC) [44], brain tumor [45,46], choriocarcinoma
[47], prostate cancer [48], and SCC of the cervix [19,
49,50]. These changes in glycoprotein expression may
play important roles in tumor grade, invasion, metastatic
ability, and clinical outcome [13,18,21,30,32–34,38–
40,42,44,46,49–51].
Altered Sialylation in SCC of the Cervix
This laboratory has demonstrated that, in SCC of the
cervix, altered expression of α2,3- and α2,6-STs, which
modify cell-surface glycosylation, correlates directly
with poor prognosis and lymph node metastasis [19,
49,51]. Expression of α2,6-STGal I was highest in
cancers with more malignant behaviors such as poor
differentiation, deep stromal invasion, lymphovascular
space involvement, and lymph node metastases [49].
Similarly, α2,3-ST III is highly expressed in cancers with
lymph node metastases: although initial expression
can be down-regulated [19], during disease progression
with lymph node metastases, expression of α2,3-ST III
is paradoxically up-regulated. The positive correlation
between α2,3-ST III and lymph node metastases is
more specific than that between α2,6-STGal I and
lymph node metastases, because only lymph node meta-
stasis can predict increased α2,3-ST III mRNA expres-
sion, but nearly all conventional poor prognostic fac-
tors, including poor differentiation, deep stromal inva-
sion, and lymphovascular space involvement, can predict
increased α2,6-STGal I mRNA expression [49]. Together,
these data suggest that an early event in oncogenesis of
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SCC of the cervix is up-regulation of α2,6-STGal I, and
its positive feedback control is associated with tumor
growth and spread. A following event might be over-
expression of α2,3-ST III, which shows a significant as-
sociation with lymph node metastasis in International
Federation of Obstetrics and Gynecology (FIGO) IB1
cervical SCC patients. Using this biologic model for
monitoring lymph node metastases, this laboratory
highlighted the possibility that finding factors to
overcome the progressive stage of cancer could lead to
changes in the first therapeutic approach [49].
Cell Surface Sialic Acid Levels Mainly
Controlled at Sialyltransferase mRNA Levels
Cell surface sialic acid levels are mainly controlled at the
mRNA level of ST genes [52]. Northern blotting has
revealed that each ST gene is expressed in a tissue-
specific manner, suggesting that transcription of the
specific ST genes is also regulated in a tissue-specific
manner [52,53]. For example, in humans, α2,6-STGal I
is expressed by many tissues, but at dramatically dif-
ferent levels [54–56]. Changes in α2,6-STGal I expres-
sion have been observed in cancerous tissues and cells,
and regulation of its expression is achieved transcrip-
tionally through tissue-specific promoters that lead to
the production of mRNA species which diverge in the
5’-untranslated region [35,57–64]. Multiple promoters
are found in the α2,6-STGal I, α2,3-ST IV, α2,3-ST V
(GM3 synthase), and α2,3-ST VI genes. These promoters
may respond to different physiologic signals and stimuli
in different cell types. Cell type-specific transcriptional
regulation of α2,6-STGal I has been studied most
thoroughly. Three major mRNA species have been cloned
from human sources [37,54]. The first, from a placenta
cDNA library, contains the 5’-untranslated exons Y and
Z (placental or Y+Z form: 250 bp) and is thought to
represent the basal or housekeeping expression of the
gene [59–62]. A second species lacks exons Y and Z but
contains a specific sequence in front of exon I and
represents the major liver transcript (hepatic or H form:
446 bp) [57,59,62]. The hepatocyte-specific promoter
P1 (part of the liver transcript) has hepatocyte nuclear
factor-1 (HNF1), activator protein 2 (AP2), and nuclear
factor-interleukin 6 (NF-IL6) binding sites [57]. HNF1
consists of liver-enriched factors that are thought to
participate in the hepatocyte specificity of P1 promoter
activity. Xu et al characterized the P1 promoter region,
which regulates Form 1 mRNA expression, using luci-
ferase assays, and showed that the nt-156 to -1 region,
which contains the HNF1 recognition element, is
important for the transcriptional activity of the α2,6-
STGal I gene in colon adenocarcinoma cell lines, because
mutation of the HNF1 site reduced luciferase activity by
about 80% compared with the wild-type construct [65].
The third form, specific to B-lymphocytes, lacks exons Y
and Z but contains the 5’-untranslated exon X (X form
or X transcript: 128 bp) [56,58,64]. The mature B lym-
phocyte cell line-specific promoter P2 (part of the X
transcript) has NF1-κB, C/EBP (CCAAT enhancer
binding protein), AP2, and NF-IL6 binding sites [57].
These factors may be important for B cell-specific
regulation of the α2,6-STGal I gene, suggesting that cell
type-specific regulation of the α2,6-STGal I gene is
controlled by both specific promoter utilization and cell
type-specific transcriptional factors, which allows
quantitative regulation of α2,6-STGal I expression [63].
Wang et al found that in SCC of the cervix, enhanced
α2,6-STGal I mRNA expression is not only associated
with more invasive characteristics, such as deep stromal
involvement, poor differentiation, and presence of
lymphovascular invasion [19], but is also more frequently
associated with lymph node metastases than with FIGO
IB1 disease without lymph node metastases [49]. In
SCC of the cervix, the presence of at least two different
transcripts of ST6Gal I mRNA indicates that the gene
may be transcribed through the use of both the
“constitutive” promoter (Y+Z form) and the “hepatic”
promoter in both normal and cancerous cervical tissue.
However, the hepatic transcript is significantly enhanced
during cancer transformation. Over-expression of the
hepatic transcript might contribute to the general
increase in α2,6-STGal I mRNA in cancerous cervical
tissue, although Dall’Olio and colleagues reported that
both the Y+Z and hepatic transcripts contribute to the
total pool of α2,6-STGal I mRNA in normal and
cancerous tissues [66]. The hepatic transcript shows a
higher translational efficiency in vitro [55], so reactivation
of the hepatic transcript in cancer transformation will
permit a higher yield of α2,6-STGal I mRNA, especially
in cervical cancer.
Complexity of Individual Sialyltransferase
mRNA Forms
The original structures and chromosomal location of
α2,3-ST IV genes have been determined [67,68]. Multiple
mRNA forms that differ only in the 5’-untranslated
region have also been identified for α2,3-ST IV. The
mRNAs of α2,3-ST IV in the human placenta and a
keratinocyte cell line consist of many isoforms, A1, A2,
B1, B2, B3, and BX [68,69]. These transcripts are
produced by a combination of alternative splicing and
promoter use, which suggests that the transcriptional
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regulation of α2,3-ST IV depends on the use of alternative
promoters [70]. The α2,3-ST IV mRNAs are transcribed
from different promoters, pA, pB1, pB2, pB3, and pBX,
respectively [51]. Type B mRNAs are expressed in several
cells, whereas type A mRNAs are specifically expressed
in the testis, ovary, and placenta, suggesting that pA
promoter activity is especially high in these tissues [52].
Taniguchi and Matsumoto suggest that the epithelial
cell-specific regulation of the α2,3-ST IV gene is mediated
by specific interaction between AP2 and the up-stream
nt -520 to -420 element [69]. AP2 belongs to transcription
factors involved in epithelium cell-specific gene expres-
sion [71,72]. Grahn et al cloned and sequenced human
α2,3-ST3 III gene transcripts from human peripheral
blood leukocytes, covering the coding region of the gene,
and isolated 19 different transcripts with a wide variety
of deletions from 45 to 896 nucleotides and insertions of
26 to 173 nucleotides, suggesting a wide variety in α2,3-
ST III gene expression in peripheral blood leukocytes
[73]. Taniguchi et al found that, in transcriptional regu-
lation of the α2,3-ST III gene, the transcription initia-
tion sites map to -181 bp from the translation site in four
cell lines (K-562, HT-29, PC-3, and HepG2), and that
the α2,3-ST III gene does not have multiple mRNAs, as
has been identified for α2,3-ST IV to VI [74]. They also
noted that the 5’-untranslated region was divided into
two exons, E1 and E2, indicating that the transcriptional
regulation of α2,3-ST III depends on the pIII promoter
that exists 5’-upstream of exon E1, and that ubiquitous
transcription factors, such as Sp1 (selective promoter
factor 1), may be important for α2,3-ST III gene expression
[74]. Thus, cell type-specific transcriptional regulation
of different ST genes is controlled by cell type-specific
transcriptional factors.
Ovarian Cancers
Carcinoma of the ovary is still the most lethal female
cancer in Taiwan, although it is not the most common
disease. The prognosis of ovarian cancer depends on
many factors, most of which are based on clinical and
histopathologic parameters including stage, differen-
tiation, and cell type [75–80]. Among these factors, the
most important is tumor stage [76]. However, the symp-
toms and signs of ovarian cancer are indolent and non-
specific, which delays accurate diagnosis [75], so
more than two-thirds of patients are diagnosed at
advanced stages (stages III and IV), for which the 5-
year survival rate is less than 20% [75]. The standard
treatment for ovarian cancer is optimal debulking
surgery followed by postoperative taxol/cisplatin-
based chemotherapy [79,80]. Despite intensive treat-
ment, at least half of these patients will suffer from
persistent or recurrent ovarian carcinomas, and finally
die of the disease [79]. Recent advances in cell and
molecular biology have improved our understanding of
the possible mechanisms underlying tissue differen-
tiation, malignant transformation, and host–tumor
interactions [81]. Elucidation of the pathways of pro-
grammed cell death and cell-cycle control has identified
several genes that play a central role in maintaining
the integrity of the genome and regulating the cell
cycle. Specific gene alterations have been associated
with sporadic or hereditary tumors and cell response
to chemotherapy [82]. Tumor migration, invasion,
metastasis, and angiogenesis are being elucidated at
a molecular level. The immune response to tumors has
also been extensively studied, and particular defects
have been identified in patients with established
malignancies. This growing bulk of information has
allowed the design of specific molecular strategies aimed
at suppressing tumor growth and controlling tumor
progression. Several approaches have emerged as po-
tentially promising, and some are being tested in the
management of epithelial ovarian cancers. However, no
evidence so far supports these approaches as better
than conventional therapy. Therefore, evaluation of
more specific and sensitive biologic targets in ovarian
cancers remains of interest. Among these biologic tar-
gets, sialic acids may be one of the most promising mole-
cules because they are involved in cell–cell and cell–
matrix interactions and cellular recognition [24,25], all
of which are closely related to tumor migration, inva-
sion, metastasis, and tumor–host interaction.
Altered Glycoproteins in Ovarian Cancers
The antigenicity of one glycoprotein, mucin (MUC1), is
altered in ovarian cancer, and anti-MUC1 antibodies
can be used as a diagnostic tool to detect the cancer
[83]. In addition, cytotoxic T-cells from malignant
ovarian tumors target the MUC1 mucin core peptide
and can lyse B-cell lines expressing either MUC1 or
MUC1 peptides from the tandem repeat region; this
lysis is inhibited by antibodies directed against the
MUC1 tandem repeat region [84]. The most frequently
used serum marker either in screening or post-treatment
follow-up of ovarian cancer, CA125 (cancer antigen
125), is a mucin-like glycoprotein that appears in most
epithelial ovarian cancers, although it may also be pre-
sent in benign ovarian disease or endometriosis [83].
CA125 is isolated from OVCAR-3 ovarian cancer cells
using a monoclonal antibody, and is rich in O-glycans
with core 2 structures and Lex and Ley determinants
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[85]. Sialyl-Tn and Tn antigens are highly expressed in
ovarian tumors and this seems to be an early event
during carcinogenesis [86,87]. Moreover, sialyl-Tn
antigen is usually found in tumors but not usually in
normal mucosa. Mucins expressing the sialyl-Tn antigen
may be secreted from the tumor and appear in the
blood. Inoue et al found that serum sialyl-Tn antigen
was significantly elevated at a cutoff of 39 U/mL:
clinical stage I, 31%; stage II, 29%; and stage III, 69%;
the antigen level was also correlated with the effect
of treatment [88]. However, the lack of tumor speci-
ficity of sialyl-Tn antigen limits its diagnostic value in
gynecologic malignancies, although serial measure-
ment appears to be useful for monitoring patients and
evaluating therapy [88]. Kobayashi et al found that the
presence of sialyl-Tn antigen in the serum of ovarian
cancer patients is associated with a poor prognosis [89].
The reasons for elevated sialyl-Tn antigen expression
have not been clarified, but several possible mechanisms
have been proposed. Enzyme relocalization: if polypep-
tide α-GalNAc-transferase is present in later Golgi
compartments, the synthesis of the core structure may
no longer be possible; alternatively, the α6-ST may be
localized to early compartments, and its action would
block the synthesis of the core structure. Block in
core synthesis: human LSC (sub-clone derived from
LS174T human colon cancer cells, ATCC number
CL-188) colon cancer cell lines have a block in O-
glycan core 1 and 3 synthesis and cannot make the
core structure 1-4; therefore, GalNAc is available for
sialyl-Tn synthesis. Loss of O-acetylation: in the normal
colon, changes in sialic acids of mucins are largely
O-acetylation decreases, leading to the exposure of
free sialic acid and recognition of the sialyl-Tn antigen
by antibodies [83].
A number of other glycoproteins, including
haptoglobin and α1-proteinase inhibitor, are also
abnormally glycosylated in ovarian cancers [83].
Haptoglobin contains more fucose (Fuc) residues in
patients with ovarian cancer, and this corresponds to
higher activities of α2-, α3- and particularly α4-Fuc-
transferase [90,91]. There is growing evidence that
these molecules act as good markers in ovarian cancer
either in screening, diagnosis, or post-therapeutic follow-
up. Therefore, it is rational to evaluate the relationship
between cell surface sialylation changes or changes in
cellular sialyltransferase activity or expression and ovar-
ian disease, progression, invasion, and metastases.
Furthermore, it is reasonable to evaluate the possible
regulation system that controls these changes in ovarian
benign or malignant diseases.
Mucins, the main class of O-glycosylated glyco-
proteins, are of very large molecular weight, and have
Ser/Thr/Pro-rich tandem repeat regions that are heavily
O-glycosylated [83]. At least nine human mucins, which
can be secreted or membrane-bound, have been cha-
racterized [83]. Cancer cells contain membrane-bound
mucin-like glycoproteins that have O-glycan-rich
domains, and O-glycans play important roles in the
attachment and invasion of cancer cells and their survi-
val in the blood stream.
Altered Sialylation is Related to Tumor
Migration and Adhesion
The interactions between tumor cells and endothelial
cells, the attachment and invasion of tumor cells through
the endothelium via binding of selectins to their ligands,
may be an important step in the metastatic process
[83]. Tumor cells with mucin type O-glycans and sialyl-
Lex ligands readily bind to E-selectins on activated
endothelium [92–94]. In several models of metastasis,
O-glycans are critical for the formation of metastases
[83,95,96]. Inhibition of O-glycan extension by GalNAc-
benzyl prevents this binding of human colon cancer cells
to E-selectin, and reduces liver metastases of LS174T
human cancer cells in nude mice [97]. Since the
expression of Lewis antigens can be inhibited with
GalNAc-benzyl, these appear to be mainly attached to
O-glycans [98,99]. While sialyl-Lex attached to O-glycans
may promote cell adhesion and invasiveness, other O-
glycan structures may also play important roles on
cancer cell surfaces [100]. Compared to primary tumors,
the expression of Tn and T antigens is decreased in
metastatic colon cancer cells, with a corresponding
increase in sialyl-Tn, sialyl-T, sialyl-Lea, and sialyl-Lex
[101]. The tissue distribution of sialyl-Tn and Ley anti-
gens differs significantly between primary tumors and
metastases of cervical cancer [100]. GalNAc-benzyl
treatment of B16 L6 melanoma cells increases peanut
agglutinin (PNA) binding, probably due to the exposure
of the T antigen on its cell surface, which results in en-
hanced adhesion of tumor cells to activated endothelial
cells or platelets mediated by ELAM-1 (E-selectin) or
GMP-140 (P-selectin), and reduces sialylation of CD44
while enhancing metastatic capacity [94].
In variants of human KM12 colon cancer cells, the
expression of sialyl-dimeric Lex attached to mucin-type
chains corresponds to high invasiveness [102]. Sialyl-
dimeric Lex is frequently increased in metastatic colon
cancer [103,104]. These sialylated Lewis structures may
play roles in cancer other than through their selectin-
binding properties. Sialic acid has repeatedly been
implicated in the metastatic process [105]. Inhibition of
sialylation and O-glycan extension and sialylation re-
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duces the metastatic potential of cancer cells [97,106].
Metastatic colon cancer cells produce hypersialylated
mucins, which appear to play an important role in cell
adhesion [107,108]. It is possible that chains carrying
sialic acid may regulate the interaction of cancer cells
with other cells and with the cell matrix. These chains
may therefore be responsible for adhesion as well as
anti-adhesion, and for extending the survival times of
cancer cells in the blood stream. Sialic acid may also
be involved in growth regulation [109]. Because sialyl-
glycoconjugates regulate adhesion and promote mo-
tility, they may be important for the colonization and
metastatic potential of cancer cells [110–112].
Monoclonal Antibodies and Lectin:
Excellent Tools to Study Change in Cell-
surface Carbohydrate-binding Proteins
In pathology, the approach to finding an aberrant antigen
expressed in malignant cells is to detect such antigens
in paraffin-embedded specimens by histochemical
methods, an approach that is very important because
pathologists can use archival collections of tissue blocks
[113]. To study carbohydrate-binding proteins, the
best tool is monoclonal antibodies, which need more
complicated preparation. Therefore, various lectins are
used as a good alternative to study changes in surface
carbohydrates. A lectin is a carbohydrate-binding protein
of non-immune origin that agglutinates glycoconju-
gate polysaccharides, which makes lectin-anti-lectin
immunohistochemistry a useful method for detecting
specific lectin-binding cell-surface antigens [114–116].
Lectins are widely used in many fields, ranging from
medical to chemical research [117]. The carbohydrate
targets of several lectins are related to tumor progres-
sion and metastasis [113]. Two groups independently
reported that Ulex europaeus-I agglutinin (UEA-I) binds
to normal colonic epithelium of the right colon but
shows no positive staining in material from the left
colon or rectum [118–121]. UEA-I lectin not only shows
regional distribution in its reactivity, but also positive
staining with high frequency in carcinomas of the
colon and rectum. In addition, there are differences in
molecular weight between UEA-I-binding glycoproteins
from normal epithelium from the left colon and from
carcinoma tissue, and these molecules are related to
carcinoembryonic antigen. UEA-I lectin specifically binds
to fucosylated type-II blood group H antigen, and the
expression of high-molecular-weight fucosylated
glycoprotein detected by UEA-I is increased in carcinoma
compared to normal mucosa, but is low in primary
tumors that have already produced metastases [121].
Boland et al used several lectins and reported stepwise
alteration in the lectin-binding pattern between normal
colonic epithelium and carcinomas [122–124]. Boland
et al and Cooper and Reuter used PNA, which has
specificity for the T antigen (Galβ1-3GalNAcα-O-Ser/
Thr), for a lectin-immunohistochemical study of polyps
of the colon and rectum [124,125]. Boland et al reported
stepwise increases in PNA binding from benign tubular
adenoma (7%), benign villo-glandular adenomas (26%),
and adenoma-containing cancer (41%) [123]. Cooper
and Reuter also reported a stepwise increase in expression
of T antigen in the apical cytoplasm and/or glycocalyx of
non-mucinous cells of tubular adenoma (25%), villous
adenoma (43%), and the adenomatous part of adenoma
with in situ carcinoma (60%) [125]. Almost 80% of in situ
carcinoma cells express PNA in an apical cytoplasmic
and/or glycocalyx pattern. These findings support con-
tinuous progression of epithelial malignancies in the
colon and rectum. The localization of T antigen is dif-
ferent in the normal colonic epithelium, in adenomas,
and in carcinomas, indicating incomplete glycosylation.
Irimura and colleagues used another type of lectin,
wheat germ agglutinin (WGA), which binds to sialic acid
and (GlcNAc)n, and reported that the expression of
WGA-binding high-molecular-weight mucin is increased
in highly metastatic cell lines relative to parental cell
lines, and is increased in metastatic lesions in studies
using animal models [126]. There are several reports of
metastasis-related lectins [127,128]. These reports im-
ply that altered carbohydrate expression is related to
altered biologic function in malignant cells, including
tumor progression and metastasis formation. How-
ever, a one-to-one correspondence between a lectin
and a carbohydrate antigen is sometimes difficult to
prove. Lectin binding to oligosaccharide structures in
some cases is very specific, but in other cases, it is not as
strict as a monoclonal antibody; however, a lectin is
more easily and conveniently used than a monoclonal
antibody.
Specific Findings Using a Specific
Anti-sialyltransferase Inhibitor
Finally, recent studies in this laboratory on the specific
cell-permeable anti-sialyltransferase, soyasaponin I
(SsaI) [20], showed very impressive findings (unpub-
lished data). SsaI inhibited cellular α2,3-ST activity
and expression of cell surface α2,3-sialic acids on
MCF-7 breast cancer cells. It also enhanced the adhe-
sion of MCF-7 cells to the extracellular matrix. SsaI had
no effect on the migration of MCF-7 cells, but significantly
decreased the migration ability of a highly metastatic
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breast cancer cell line, MDA-MB-231. We believe that
future experiments may elucidate the functional roles of
STs in cancer pathogenesis.
Conclusion
Altered sialylation is very common in certain patho-
logic conditions, including cancer transformation and
cancer metastasis. Advanced molecular biology
techniques allow more insight into the importance of
sialylation.
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